AESTHER HEALTHCARE ACQUISITION


Associated tags: Ocean Biomedical, SPAC, Security (finance), Vaccine, Pulmonary fibrosis, Malaria, Research, Lung cancer, Patient, Brain, Brown University, CHI3L1, Fibrosis, RI

Locations: SPAC

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce the Award of New Patents for Novel Monospecific and Bispecific Antibodies that Suppress Multiple Cancer Types

Retrieved on: 
Thursday, February 9, 2023
Fibrosis, Antibody, Journal, Brown University, PD-1, Composition, Lung cancer, Cancer, Biology, RI, Prostate cancer, Colorectal cancer, Kidney cancer, PTEN, Breast cancer, Patient, Apoptosis, Ovarian cancer, Patent, CTLA4, Neoplasm, Frontiers, Vaccine, Medical imaging, Immunology, Glioblastoma, Medicine, Melanoma, CHI3L1

Providence, RI and New York, NY, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today that Scientific Co-founder Dr. Jack A. Elias has been awarded multiple patents for his discoveries related to suppressing tumors by regulating CHI3L1 and several connected pathways. Dr. Elias, the former Chair of Yale’s Department of Medicine, and the Dean Emeritus of Medicine and Biological Sciences at Brown University, has been granted Methods and Compositions patents for mono-specific and bi-specific antibody approaches for use in multiple cancer types, including Prostate Cancer, Colon Cancer, Rectal Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, Malignant Melanoma, and Lung Cancer.

Key Points: 
  • Multiple Patents granted for Methods and Composition for Mono-specific and Bi-specific antibody approaches that suppress tumors by targeting and neutralizing elevated levels of chitinase 3-like-1 (CHI3L1) and other mediators.
  • Dr. Elias, the former Chair of Yale’s Department of Medicine, and the Dean Emeritus of Medicine and Biological Sciences at Brown University, has been granted Methods and Compositions patents for mono-specific and bi-specific antibody approaches for use in multiple cancer types, including Prostate Cancer, Colon Cancer, Rectal Cancer, Ovarian Cancer, Kidney Cancer, Breast Cancer, Glioblastoma, Melanoma, Malignant Melanoma, and Lung Cancer.
  • In accord with the importance of these pathways, he has also generated antibodies: 1.)
  • We look forward to working with Ocean Biomedical to bring all of these therapies to patients, for the long-term shareholder value and the continued advancement of medical science.”

Aesther and Ocean Biomedical Announce Shareholder Approval of Business Combination

Retrieved on: 
Monday, February 6, 2023
Benchmark, Bangladesh Securities and Exchange Commission, Fibrosis, Security (finance), Malaria, Pulmonary fibrosis, Acquisition, LLP, Infection, Vaccine, Dykema Gossett, EF Hutton, Nelson Mullins Riley & Scarborough, Tuberculosis, CHI3L1, Brown University, Management, Pharmaceutical industry

NEW YORK and PROVIDENCE, R.I, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (“SPAC”) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company, today announced that its stockholders approved all proposals related to the previously announced proposed business combination between Aesther and Ocean at a special meeting of stockholders held on February 3, 2023.

Key Points: 
  • NEW YORK and PROVIDENCE, R.I, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (“SPAC”) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company, today announced that its stockholders approved all proposals related to the previously announced proposed business combination between Aesther and Ocean at a special meeting of stockholders held on February 3, 2023.
  • “The business combination with Aesther brings us one step closer to realizing our foremost goals as an innovative life sciences company.”
    “The future is unquestionably bright for Ocean Biomedical,” said Suren Ajjarapu, Chairman and CEO of Aesther.
  • Various fibrotic diseases may be vulnerable to the effects of the OCF-203 pathway inhibitor Chitinase 1 (Chit1), also identified by Ocean.
  • Ocean and Aesther have partnered with some of the premier investment institutions in the health care space.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Measures regarding Excise Tax

Retrieved on: 
Wednesday, February 1, 2023
Bank account, Trust, Excise, Acquisition, Excise tax in the United States, Interest on Lawyer Trust Accounts, SPAC, Security (finance), Insurance

NEW YORK and PROVIDENCE, R.I., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther’s stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.

Key Points: 
  • NEW YORK and PROVIDENCE, R.I., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther’s stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.
  • Aesther and Ocean are issuing this press release to notify all concerned parties regarding Aesther and Ocean’s commitment to retain sufficient funds in its Trust Account to pay for any Excise Tax liabilities that may arise.
  • As disclosed in the Definitive Proxy Statement, Aesther or the post-combination company may be liable to pay Excise Taxes.
  • Aesther, Ocean and the post-combination company will not, under any circumstances, withdraw any amounts from the Trust Account, including interest earned on the Trust Account, to pay for the Excise Tax.

Ocean Biomedical and Aesther Healthcare Acquisition Corp. Announce Publication of Discovery Data for a Major Anti-Tumor Pathway in Malignant Melanoma and Other Cancers

Retrieved on: 
Monday, January 30, 2023
B7-1, Antibody, Fibrosis, Metastasis, Skin cancer, Melanoma, Cluster, Journal, PD-1, Large-cell lung carcinoma, Cancer, Biology, NSCLC, B7-2, RI, Outline, Lung, PTEN, Patient, ICOS, CD28, Apoptosis, Glioblastoma, CTLA4, Neoplasm, Research, Vaccine, Medical imaging, Immunology, CHI3L1, Medicine, Frontiers

Providence, RI and New York, NY, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today the discovery of a second major anti-tumor pathway and therapeutic approach that targets CTLA-4, inhibiting the metastasis of malignant melanoma cells to the lung using a novel bispecific antibody approach. This major regulating mechanism discovery, recently published in Frontiers in Immunology, by Ocean Biomedical’s Scientific Co-founder and Brown University’s Emeritus Dean of Medicine and Biological Sciences, Dr. Jack A. Elias, builds on his team’s prior discoveries that target Chitinase 3-like-1 (CHI3LI) and its role in inhibiting T-cell proliferation. Additionally, this promising research reveals a third anti-tumor pathway targeting T-cell co-stimulation using the inducible co-stimulator (ICOS) and its ligand ICOSL, and Cluster of Differentiation 28 (CD28) and its ligands B7-1 and B7-2. Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.

Key Points: 
  • Ocean Biomedical’s novel approach to tumor suppression, focused on controlling CHI3LI, other immune checkpoint inhibitors, and T-cell co-stimulators, has potential application for tumor suppression across multiple cancer pathways.
  • “If you control CH3L1, you don’t just control one anti-cancer pathway, you simultaneously control many anti-cancer pathways.
  • Malignant melanoma, a very serious skin cancer with a 22.5% five-year survival for patients with Stage IV disease, can metastasize to other organs.
  • We look forward to working with Ocean Biomedical to bring all of these therapies to patients, for the long-term shareholder value and the continued advancement of medical science.”

Ocean Biomedical Provides Corporate Update and Company Summary

Retrieved on: 
Tuesday, January 24, 2023
Benchmark, Disease, Infection, Hermansky–Pudlak syndrome, Pulmonary fibrosis, Scleroderma, Lung cancer, SPAC, Research, Brown University, Fibrosis, Malaria, Yale University, Technology transfer, Glioblastoma, Harvard University, Non-small-cell lung carcinoma, Business architecture, Biomedicine, Nelson Mullins Riley & Scarborough, Stanford University, Prevalence, NSCLC, NASH, HPS, Tuberculosis, Brain, CHI3L1, Alcoholic liver disease, Idiopathic pulmonary fibrosis, Human, Acquisition, Cancer, LLP, Risk, Dykema Gossett, RI, EF Hutton, GBM, Patient, Growth, Pharmaceutical industry, Vaccine

PROVIDENCE, RI and NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities. Built on Ocean Biomedical’s expertise in technology transfer, a unique business model was created to bridge the ‘bench-to-bedside’ gap and accelerate the commercialization of novel assets from leading research universities and medical centers. Ocean Biomedical is expected to become a publicly traded company on NASDAQ under the symbols “OCEA” and “OCEAW” following the expected closing of a Business Combination with Aesther Corporation.

Key Points: 
  • PROVIDENCE, RI and NEW YORK, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical (“Ocean”), a next-generation biopharma company, and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA), a publicly traded special purpose acquisition company (SPAC), shared today an update on key company activities.
  • Ocean Biomedical is expected to become a publicly traded company on NASDAQ under the symbols “OCEA” and “OCEAW” following the expected closing of a Business Combination with Aesther Corporation .
  • “The scientific and operational progress Ocean Biomedical has had to date, even without access to the public markets, is astounding – the company is at an inflection point, with multiple ways to win.
  • Each of these assets are progressing towards the next stage of their development pipelines,” said Dr. Chirinjeev Kathuria, Ocean Biomedical co-founder and Executive Chairman of the Board of Directors.

Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc.

Retrieved on: 
Friday, January 13, 2023
Special, SPAC, Common stock, Acquisition, Security (finance)

NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther’s stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.

Key Points: 
  • NEW YORK and PROVIDENCE, R.I., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) (“Aesther”), a special purpose acquisition company (SPAC) and Ocean Biomedical, Inc. (“Ocean”), a next-generation biopharma company announced today that AEHA has filed with the U.S. Securities and Exchange Commission ("SEC") a definitive proxy statement (“Definitive Proxy Statement") in connection with its proposed business combination (the “Business Combination” or the “Transaction”) with Ocean and with respect to the special meeting of Aesther’s stockholders (“Special Meeting”) scheduled to be held on February 3, 2023.
  • The Definitive Proxy Statement and related materials will be mailed to the stockholders of Aesther on or about January 13, 2023.
  • Aesther’s stockholders will have until February 1, 2023 (two (2) business days before the Special Meeting) to have their shares of Class A Common Stock redeemed for cash in connection with the matters to be voted on at the Special Meeting, as described in the Definitive Proxy Statement.
  • A link to the Definitive Proxy Statement, as well as other information related to the Transaction can be found via AEHA’s filings with the SEC at www.sec.gov .

Aesther Healthcare Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Business Combination

Retrieved on: 
Friday, December 16, 2022
Transfer, Tripura Merger Agreement, Acquisition, Pulmonary fibrosis, 100,000, Madison Avenue, Communication, Failure, Person, Ix, Lung cancer, Sale, Suite, Probability, XV, University, Mergers and acquisitions, Brain, Transaction, Name, Malaria, Attention, Proxy, Growth, Research, Investment, Risk, COVID-19, SPAC, Therapy, Risk management, Security (finance)

About Aesther Healthcare Acquisition Corp.

Key Points: 
  • About Aesther Healthcare Acquisition Corp.
    Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical.
  • Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world.
  • Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.

Aesther Healthcare Acquisition Corp. Announces Intention to Extend Period to Consummate Business Combination

Retrieved on: 
Tuesday, December 13, 2022
Tripura Merger Agreement, Acquisition, Pulmonary fibrosis, 100,000, Madison Avenue, Communication, Failure, Person, Ix, Lung cancer, Sale, Suite, Probability, XV, University, Mergers and acquisitions, Brain, Transaction, Name, Malaria, Attention, Proxy, Growth, Research, Investment, Risk, COVID-19, SPAC, Therapy, Risk management, Security (finance)

About Aesther Healthcare Acquisition Corp.

Key Points: 
  • About Aesther Healthcare Acquisition Corp.
    Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
  • Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical.
  • Neither of Ocean Biomedical or Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations.
  • Such information with respect to Ocean Biomedical’s directors and executive officers will also be included in the proxy statement.

Novel Malaria Drug Discovery Presented at the ASTMH Tropical Medicine Meeting by Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis, unveiling the potential for a new class of Antimalarial Drugs.

Retrieved on: 
Tuesday, November 1, 2022
Growth, Ix, Apoptosis, Tropical medicine, SEC, GLOBE, Research, Antibody, COVID-19, Lung cancer, Attention, Human, Artemisinin, Brown University, Joint Medical Service (Germany), Brain, Investment, FDA, Pulmonary fibrosis, Madison Avenue, Failure, Risk, CEO, Transaction, Person, Suite, Safety, NASDAQ, Malaria, U.S. Securities and Exchange Commission, Patient, Medical laboratory, 100,000, Proxy, Therapy, Infection, Parasitism, RI, Parasitemia, Acquisition, Plasmodium, Nasdaq, University, Mergers and acquisitions, Communication, Death, SPAC, Tripura Merger Agreement, Pathology, Name, Society, Sale, Vaccine, XV, Probability, Hygiene, Forward-looking statement, Medical device, Pharmaceutical industry, Security (finance), Nature

Providence, RI and New York, NY, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) announced today that Scientific Co-founder, Dr. Jake Kurtis, will present groundbreaking research discoveries at this week’s Annual Meeting of The American Society of Tropical Medicine and Hygiene. These discoveries have the potential to launch a whole new class of antimalarial drugs, and come at time when current artemisinin-based treatments are beginning to lose efficacy.

Key Points: 
  • Along with the related vaccine program, this small molecule drug program will be a key focus of Ocean Biomedicals development pipeline in 2023.
  • Malaria caused by infection with Plasmodium parasites is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals last year.
  • Suren Ajjarapu, Chairman and CEO of Aesther, commented, Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today.
  • Such information with respect to Ocean Biomedical's directors and executive officers will also be included in the proxy statement.